Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05239741 |
TitleStudy of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) | Phase
Phase 3
|
Date Added 2022-02-15 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
5-Fluorouracil, Irinotecan, Leucovorin, oxaliplatin |
Tags
MSI-H/ MMRd
|
| NCT ID NCT03638297 |
TitlePD-1 Antibody Combined With COX Inhibitor in MSI-H/dMMR or High TMB Colorectal Cancer | Phase
Phase 2
|
Date Added 2018-08-20 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
PD-1 antibody + cox inhibitor |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05722327 |
TitlePhase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer | Phase
Phase 1
|
Date Added 2023-02-10 |
Location
Texas, United States
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
cetuximab, Irinotecan, MRTX849 |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT05733611 |
TitleRP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC | Phase
Phase 2
|
Date Added 2023-02-17 |
Location |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs |
Tags
MSS/ MMRp
|
| NCT ID NCT05784688 |
TitleStudy of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Phase
Phase 1, Phase 2
|
Date Added 2023-03-27 |
Location
Texas, United States
Washington, United States Korea, Republic of |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
TU2218 + Pembrolizumab |
Tags
MSS/ MMRp
|
| NCT ID NCT05838768 |
TitleStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency. | Phase
Phase 1
|
Date Added 2023-05-03 |
Location
California, United States
Massachusetts, United States New York, United States Texas, United States Belgium China France Germany Israel Italy Japan Norway Singapore South Korea Spain Sweden Taiwan United Kingdom |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
HRO761, Irinotecan |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05770102 |
TitleDETERMINE Trial Treatment Arm 2: Atezolizumab in Adult, Teenage/Young Adults and Paediatric Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition | Phase
Phase 2, Phase 3
|
Date Added 2023-03-15 |
Location
United Kingdom
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Atezolizumab |
Tags
MSI-H/ MMRd
|
| NCT ID NCT05771181 |
TitleVitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients | Phase
Phase 2
|
Date Added 2023-03-16 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Fruquintinib, Tislelizumab, Vitamin E |
Tags
MSS/ MMRp
|
| NCT ID NCT05684211 |
TitleA Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer | Phase
Phase 2
|
Date Added 2023-01-13 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Not yet recruiting
|
Drugs
Ametumumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04595266 |
TitleChemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease | Phase
Phase 2
|
Date Added 2020-10-20 |
Location
Spain
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Anti-EGFR or Bevacizumab, FOLFOX regimen, LIVERPEARLS-Irinotecan |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
